SEC Form 4 · accession 0001144204-15-021895
INTERLEUKIN GENETICS INC · ILIU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark B Carbeau
Officer — Chief Executive Officer · Director
Period of report
Apr 6, 2015
Accepted (ET)
Apr 8, 2015 · 7:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001037649
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $0.1525 | Apr 6, 2015 | A | 14,245,227 | A | — | Apr 6, 2025 | Common Stock | 14,245,227 | 14,245,227 | D |
Explanation of responses
- F1The exercise price of the option is the closing price of the Issuer's common stock on the OTCQB on 4/6/2015, which was the grant date of the option.
- F2The option vests as to 25% of the shares on April 6, 2016 and as to 2.083% of the shares on the last day of each successive month thereafter.